All News

A patient with an advanced solid tumor was given their first dose of a novel antibody, kicking off a phase 1/1b study comparing this drug with or without Keytruda in patients with several types of solid tumors.

Certain patients with metastatic breast cancer may benefit from Enhertu compared with standard of care with Kadcyla despite higher rates of side effects including lung inflammation and interstitial lung disease.

When visiting the cancer center (or any other health care center), the people who greet me at the front desk can have a major impact on the whole experience.

The FDA’s decision to approve Yescarta in patients with large B-cell lymphoma that has failed to respond to first-line treatment is based on data that showed that the use of the CAR-T cell therapy resulted in a significant increase in patients who were alive at two years compared with the standard-of-care second-line treatment.

Watch Dr. Saad Z. Usmani, Dr. Krina K. Patel, Dr. Noa Biran, and Jenny Ahlstrom, answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

The year 2022 has already been filled with obstacles and heartache — as well plans for a new cancer treatment — but I’m putting away the bad thoughts to get ready for the fight ahead of me.

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

In CURE’s Speaking Out video series, on behalf of Living Beyond Breast Cancer, Andrea Kassem discusses integrative care in metastatic breast cancer.

In CURE’s Speaking Out video series, on behalf of Living Beyond Breast Cancer, Myra Camino discusses her experience as a patient advocating for herself after her stage 4 metastatic breast cancer diagnosis.

In CURE’s Speaking Out video series, on behalf of Living Beyond Breast Cancer, Dr. Nancy Lin discusses the multidisciplinary approach to metastatic breast cancer care.

Treatment with a novel monotherapy in a patient with relapsed/refractory acute myeloid leukemia was effective enough that a successful, as indicated by a significant reduction in bone marrow blasts, stem cell transplant was performed.

Motivating affirmations are one thing, but to me, labels like “survivor” and “cancer-free” are a touchy subject.

From New York Yankees outfielder Aaron Judge giving a brain cancer survivor custom baseball cards to Tom Parker’s brain cancer death and Good Morning America’s Robin Roberts opening up about her cancer experience, here’s what is happening in the cancer space this week.

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

The FDA plans to decide on whether to approve futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors a certain genetic mutation by September.

Patients with colorectal cancer that has spread to the liver tend to have poor outcomes and are typically not candidates to receive liver transplants from deceased donors. However, results from a small study on transplanting livers from live-donors could "change this paradigm," an expert said.

Twice a week, my local Gilda’s Club holds a “Lunch and Laughs” group meeting with cancer survivors that has kept me grounded through COVID-19 isolation and beyond.

As a patient moves from treatment to survivorship, the fear of cancer recurrence may overshadow the ability for them to recognize how much they have endured, but support is available to hopefully lessen the burden.

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.

Tiragolumab plus Tecentriq and chemotherapy did not significantly improve progression-free survival and overall survival in patients with extensive-stage small-cell lung cancer.

Performing genetic testing in every patient diagnosed with colon cancer, and not just those considered high-risk, could identify that person's risk of developing another cancer later in life.

My daughter’s radiation oncologist said that certain treatments may lead to another cancer diagnosis later in her life, but isn’t living better now worth the risk?

It is expected that up to 18 patients with leptomeningeal metastases — a serious form of cancer that has spread from its original location to an area surrounding the brain and spinal cord — will receive treatment with the investigational drug.

Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.

Approximately 60 patients with metastatic/unresectable solid tumors, including bladder cancer, are expected to be enrolled onto a clinical trial assessing the safety and efficacy of Zepzelca.

Keytruda was well tolerated and demonstrated practice-changing responses with potential for a curative approach in a group of patients with advanced endometrial cancer, according to an expert.

Spring has arrived, and along with it has come fresh challenges and new perspectives regarding my cancer survivorship.